News
Those who take tirzepatide, the drug sold as Zepbound and Mounjaro, could lose more weight than those who take semaglutide, ...
Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds over 72 weeks, ...
Eli Lilly’s obesity drug Zepbound led to nearly 50 percent more weight loss than Novo Nordisk’s Wegovy in the first direct ...
Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...
A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo ...
Eli Lilly’s (LLY) and Novo Nordisk’s (NVO) weight loss drugs went head-to-head in a weight loss study for the first time — ...
The head-to-head examination of these weight loss drugs provides doctors with 'robust' data on their effectiveness.
ABC News chief medical correspondent Dr. Tara Narula breaks down what to know about a new study that says Zepbound may be ...
In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results